Healio

RelabotulinumtoxinA demonstrates rapid onset, durability for frown lines, crow’s feet

Please provide your email address to receive an email when new articles are posted on . Both phase 3b studies met their primary endpoints of improved frown lines and crow’s feet. A majority of ...
Business Wire

Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines

ZUG, Switzerland--(BUSINESS WIRE)--Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and ...
Healio

RelabotulinumtoxinA improves frown lines, crow’s feet simultaneously for up to 6 months

Please provide your email address to receive an email when new articles are posted on . When treated separately, 71% of patients treated for frown lines and 45% treated for crow’s feet saw ...
Business Wire

TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously

ZUG, Switzerland--(BUSINESS WIRE)--Galderma announced today positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of ...
Nasdaq

Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow’s Feet Lines Published in ...

Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 65.02% for PrabotulinumtoxinA and 62.56% for OnabotulinumtoxinA at Week 4 NEWPORT BEACH, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- ...